In August 2023, niraparib (not yet approved for prostate cancer) was approved in combination with abiraterone for the treatment of patients with deleterious or suspected deleterious BRCA1- or BRCA2-mutated mCRPC, based on the findings of the MAGNITUDE trial (NCT03748641) (89). Here, BRCA1 is linked to prostate carcinoma.